EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anticoagulant-Related Nephropathy: A Retrospective Analysis of the FDA Adverse Events Reporting System (FAERS) Database

Predrag Jancic, Claudiu M. Ciuciureanu, Nikola Jovanovic, Stefan Milutinovic, Dragana Stanojevic

Journal of CardioRenal Medicine · 2025

DOI: 10.3390/jcrm1010003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of CardioRenal Medicine, 2025. Verfasst von Predrag Jancic und 4 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anticoagulation is the cornerstone of thromboembolic event prevention. Adversely, anticoagulants (ACs) are linked to a variety of adverse events. We aimed to assess the link between vitamin K antagonists (VKA) and direct anticoagulant (DOACs) use and acute kidney injury (AKI) using the FDA Adverse Events Reporting System (FAERS) Database.

Methods

We conducted a disproportionality analysis on the adverse events (AEs) of interest in the FAERS database using the reporting odds ratio (ROR), proportional reporting ratio (PPR) with the Yates correction (x2yates), and the information component (IC).

Results

A total of 20,253 cases of AKI associated with use of ACs were analyzed. Edoxaban, dabigatran and warfarin showed greater association with AKI (ROR 2.63; ROR 1.46; ROR). In cases with manifest bleeding, edoxaban, dabigatran, warfarin and rivaroxaban had a stronger statistical association with AKI. Rivaroxaban showed greater association with AKI compared to other ACs when used concomitantly with Aspirin (ROR 2.25).

Conclusion

We showed increased odds of reporting AKI with use of edoxaban, dabigatran and warfarin compared to other anticoagulants. In cases with reported bleeding, AKI was more commonly reported with all five analyzed anticoagulants, except for apixaban, highlighting its favorable side-effect profile. Caution and clinical awareness are needed when prescribing ACs to vulnerable populations.

Zitieren

APA

Jancic, P., Ciuciureanu, C. M., Jovanovic, N., Milutinovic, S., & Stanojevic, D. (2025). Anticoagulant-Related Nephropathy: A Retrospective Analysis of the FDA Adverse Events Reporting System (FAERS) Database. Journal of CardioRenal Medicine. https://doi.org/10.3390/jcrm1010003

Vancouver

Jancic P, Ciuciureanu CM, Jovanovic N, Milutinovic S, Stanojevic D. Anticoagulant-Related Nephropathy: A Retrospective Analysis of the FDA Adverse Events Reporting System (FAERS) Database. Journal of CardioRenal Medicine. 2025. doi:10.3390/jcrm1010003

BibTeX
@article{Jancic2025,
  author = {Jancic, Predrag and Ciuciureanu, Claudiu M. and Jovanovic, Nikola and Milutinovic, Stefan and Stanojevic, Dragana},
  title = {Anticoagulant-Related Nephropathy: A Retrospective Analysis of the FDA Adverse Events Reporting System (FAERS) Database},
  journal = {Journal of CardioRenal Medicine},
  year = {2025},
  doi = {10.3390/jcrm1010003}
}
Kostenlos starten →